Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors-Reference-Cited by-同舟云学术

Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors

Published:2014-02-27 Issue:9 Volume:123 Page:1372-1383
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Marty Caroline¹²³,Saint-Martin Cécile¹⁴,Pecquet Christian⁵⁶,Grosjean Sarah¹⁴,Saliba Joseph¹²³,Mouton Céline⁵⁶,Leroy Emilie⁵⁶,Harutyunyan Ashot S.⁷,Abgrall Jean-François⁸,Favier Rémi¹⁹,Toussaint Aurélie¹⁰,Solary Eric¹²³,Kralovics Robert⁷¹¹,Constantinescu Stefan N.⁵⁶,Najman Albert¹²,Vainchenker William¹²³,Plo Isabelle¹²³,Bellanné-Chantelot Christine¹⁴

Affiliation:

1. Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche 1009, Laboratory of Excellence GR-Ex, Villejuif, France;

2. Université Paris XI, Unité Mixte de Recherche 1009, Institut Gustave Roussy, Villejuif, France;

3. Institut Gustave Roussy, Villejuif, France;

4. Assistance Publique-Hôpitaux de Paris, Département de Génétique, Hôpital Pitié-Salpêtrière, Université Pierre et Marie Curie, Paris, France;

5. Ludwig Institute for Cancer Research, Brussels, Belgium;

6. de Duve Institute, Université Catholique de Louvain, Brussels, Belgium;

7. Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria;

8. Centre hospitalier universitaire de Brest, Service d’Hématologie, Brest, France;

9. Assistance Publique-Hôpitaux de Paris, Service d’Hématologie Biologique, Le Centre de Référence des Pathologies Plaquettaires, Hôpital Armand Trousseau, Paris, France;

10. Assistance Publique-Hôpitaux de Paris, Service de Biochimie et Génétique Moléculaire, Groupe Hospitalier Cochin, Paris, France;

11. Division of Hematology and Blood Coagulation, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria; and

12. Assistance Publique-Hôpitaux de Paris, Service des Maladies du Sang et de Thérapie Cellulaire, Hôpital Saint-Antoine, Université Pierre et Marie Curie, Paris, France

Abstract

Key Points New germ-line mutations of JAK2 in the kinase domain were identified. Specificity for MPL and resistance to JAK2 and HSP90 inhibitors was determined.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/123/9/1372/1379281/1372.pdf

Reference32 articles.

1. From hematopoietic stem cells to platelets.;Chang;J Thromb Haemost,2007

2. Thrombocytosis.;Skoda;Hematology Am Soc Hematol Educ Program

3. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders.;Bellanné-Chantelot;Blood,2006

4. Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms.;Saint-Martin;Blood,2009

5. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.;Beer;Blood,2008

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Insights into the role of JAK2-I724T variant in myeloproliferative neoplasms from a unique cohort of New Zealand patients;Hematology;2024-01-10

2. Hereditary thrombocythemia due to splicing donor site mutation of THPO in a Japanese family;Annals of Hematology;2023-11-14

3. Molecular landscape of the JAK2 gene in chronic myeloproliferative neoplasm patients from the state of Amazonas, Brazil;Biomedical Reports;2023-10-23

4. A novel germline hyperactivating JAK2 mutation L604F;Annals of Hematology;2023-08-28

5. A novel germline hyperactivating JAK2 mutation L604F;ANN HEMATOL;2023